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ABSTRAK
Nefritis lupus (NL) adalah keterlibatan organ ginjal pada pasien lupus eritematosus sistemik (LES) dan 
merupakan salah satu keterlibatan organ yang paling sering ditemukan. Ditemukannya NL pada pasien LES 
akan berdampak besar baik secara prognosis dari pasien maupun dalam pengobatan itu sendiri. Pengobatan NL 
dibagi menjadi dua tahap, induksi dan rumatan. Target dari pengobatan tahap induksi adalah untuk secepatnya 
mencapai remisi, baik parsial ataupun komplit, karena akan memberikan prognosis yang lebih baik dan kejadian 
relapse  yang lebih rendah. Pada tahap rumatan, target yang ingin dicapai adalah untuk mempertahankan 
status remisi dan mencegah terjadinya relapse. Evaluasi keberhasilan dari masing-masing tahap juga sangat 
penting karena akan berpengaruh pada kelanjutan pengobatan. Kortikosteroid, siklofosfamid, mikofenolat 
mofetil, azatioprin, siklosporin dan takrolimus adalah obat-obat yang biasa dipakai dalam pengobatan NL. 
Berbagai target pengobatan baru juga terus berkembang guna memberikan pilihan yang lebih luas dalam 
menangani kejadian NL.
Kata kunci: lupus eritematosus sistemik; nefritis lupus, ginjal.
ABSTRACT
Lupus nephritis (LN) is involvement of the kidney in patient with systemic lupus erythematosus (SLE) and one 
of the most common target organ in SLE. The diagnosis of LN will significantly impact the clinical outcome and 
therapy of the patient. Therapy regiment of LN is divided into two stages, induction and maintenance treatment. 
The main objective of the induction therapy is to achieve complete or partial remission as soon as possible 
since it is correlated with better prognosis and fewer relapse incidence. In the maintenance stage, the main aim 
of the therapy is to maintain the remission status and avoid future relapse. It is also important to evaluate the 
effectiveness of the therapy as it will affect the duration and the regiment therapy being used. Corticosteroid, 
cyclophosphamide, mycophenolate mofetil, azathrioprine, cyclosporine and tacrolimus are example of drugs 
used in LN therapy.  Currently, studies are being conducted to evaluate and develop targeted drug therapy to 
further add treatment options for LN.
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INTRODUCTION
Renal involvement in systemic lupus 
erythematosus (SLE) plays a major factor that 
impact the clinical outcome on the patient. Lupus 
nephritis (LN) was found in 40 – 60% of SLE 
patients and can increase up to 70% over 10-year 
period after initial diagnosis.1 Recent data shows 
10-year survival of LN patient to range between 
77 to 95%.2 Despite advances in treatment, 26% 
of LN patients still develop end-stage renal 
disease (ESRD) which cause a reduced in life 
expectancy by 15.1 – 23.7 years. Infections, 
cardiovascular complication and malignancy 
contribute to the main cause of death associated 
with long-term LN treatment.3 The review aims 
to compare the regiments in terms of efficacy 
and safety for better clinical practice outcome.
CURRENT INDUCTION THERAPY
Induction therapy is pivotal in treating 
patients with lupus nephritis (LN), the goal is to 
minimize renal damage, achieve rapid remission 
and/or complete remission.4 An effective 
induction therapy has been proven to give fewer 
episodes of relapse and better prognosis.4
Induction therapy for LN patients is a 
continuously studied topic.4-6 In 1986, National 
Institutes of Health reported its 10-year follow up 
research and found that by combining high-dose 
steroids and cyclosphophamide (CYC) it gave a 
significantly better 10-year renal survival result 
than steroids alone.7 However, CYC also resulted 
various side effects such as suppression of bone 
marrow, malignancy, opportunistic infection, 
and so forth.7 Despite, administration of steroids 
combined with intravenous (IV) CYC became 
the gold standard in treating LN patients until 
present.6
Since then, researchers look for a safer 
immunosuppressants agents to replace CYC, 
for example mycophenolate mofetil (MMF), 
azathrioprine (AZA), cyclosporine, and 
tacrolimus. MMF is the most promising alternative 
for CYC, although results from literatures 
displayed various results in inducing remission 
of LN between the two immunosuppressant’s 
agents.4,6,8 Some studies concluded that MMF is 
more superior than CYC.9-11 On the other hand, 
others found that MMF is not-inferior or equal 
to CYC.12,13 Nevertheless, most clinicians favor 
the use of MMF. Unfortunately it is not covered 
in the health insurance program in Indonesia.5
Currently, researchers focus on multitarget 
induction therapy; combining multiple drugs to 
achieve better results and fewer side effects and 
shows promising results.14,15 A study in China 
compared a combination of tacrolimus, MMF, 
and steorids with the traditional IV CYC and 
steroids.13,14 The multitarget regiments showed 
a higher incidence of complete remission and 
less adverse events. A retrospective analysis in 
Japan was conducted to examine the efficacy 
and safety of multitarget induction therapy using 
tacrolimus, MMF, and steroid with comparison 
of TAC Therapy (tacrolimus and steroid).15 
It was found that all patients treated with 
multitarget therapy had complete remissions. 
A meta-analysis of randomized trials was done 
in 2017 to compare the efficacy and toxicity of 
newer immunosuppressants for LN.16 The study 
compared IV CYC, oral CYC, MMF, calcineurin 
inhibitor (CNI), plasma exchange, rituximab, 
or azathioprine, alone or in combination. The 
study stated that MMF combined with CNI 
was the most effective treatment to induce 
remission, followed by CNI alone and MMF 
alone.16 Although, it was also found that there 
was no difference on end-stage kidney disease 
or increasing of serum creatinine level between 
MMF or CCI (alone or in combination) and IV 
CYC.
According to Kidney Disease Improving 
Global Outcomes (KDIGO) 2012, the use 
of immunosuppressants are indicated for 
Class III/IV LN.17 Class V LN are also given 
immunosuppressants in regards that endocapillary 
hypercellularity and/or subendothelial immune 
deposits is present and persistent nephrotic 
proteinuria.17 Figure 1 shows the algorithm of 
induction therapy for LN.
As for Class I LN, KDIGO 2012 does not 
recommend treatment due to no available data to 
suggest that it needs therapy.17 However, Class II 
LN with proteinuria under 1 g/d should be treated 
for extrarenal clinical manifestations and Class 
II LN with uncontrolled proteinuria (over 3 g/d) 
should be treated with corticosteroids or CNIs.17
KDIGO 2012 recommended 4 regiments to 
Vol 49 • Number 4 • October 2017                                                Current and emerging therapy on lupus nephritis
371
be used in induction therapy, which are: Regimen 
A (NIH regimen), Regimen B (Euro-Lupus 
regimen), Regimen C (oral cyclosphophamide), 
and Regimen D (MMF).17 All regimens used the 
same steroid dosing: initial dose of oral prednisone 
1 mg/kg, tapering according to clinical response 
over 6-12 months. Dosage and duration of the 
regimens can be seen in Table 1. In addition, 
according to the Spanish Society of Nephrology 
(SEN) and Society of Internal Medicine (SEMI) 
dosage of Regimen B has minimum risk, almost 
to none, of ovarian failure because the total CYC 
given does not exceed 10 g.18 extrarenal manifestations must be treated with 
immunosuppression agents.17
American College of Rheumatology (ACR) 
also made a guideline for therapy of LN. MMF 
2-3 g daily or IV CYC along with IV pulse 
steroids (500-1000 mg methylprednisolone 
daily for 3 doses) for Class III/IV LN are the 
recommended regimens, and both are considered 
equivalent based on recent studies.19 There are 
2 recommended dosage for IV CYC, which are: 
low-dose CYC (500 mg IV fortnightly for a total 
of 6 doses) followed by maintenance therapy 
with daily oral AZA and high-dose CYC (500-
1000 mg/m2 IV monthly for 6 doses) followed 
by maintenance therapy with MMF or AZA.19 
Figure 2 shows the algorithm made by ACR.
Class V LN have different recommendation 
than Class III/IV LN according to ACR. They 
recommend the administration of prednisone 
(0.5 mg/kg/day) combined with MMF 2-3 g total 
Figure 1. Induction therapy algorithm according to KDIGO 2012.17
(LN = lupus nephritis; IV CYC = intravenous cyclosphophamide; CYC = cyclosphophamide; MMF = mycophenolate 
mofetil)
Table 1. Regimens for induction therapy in class III/IV LN 
according to KDIGO 201217
Regimen Dosage Duration
NIH IV CYC 0.5-1 g/m
2 
monthly 6 months
Euro-Lupus IV CYC 500 mg fortnightly 3 months
Oral 
Cyclosphophamide
Oral CYC 1-1.5 mg/
kg/day 2-4 months
MMF Oral MMF 3 g/day 6 months
If the patients have worsening LN or flare 
during the first 3 months, alternative induction 
therapy can be used as a replacement.17 Table 
2 shows the immunosuppressants used in LN.
Class VI LN is described as chronic injury, where 
over 90% of the glomeruli are sclerotic.17 KDIGO 
2012 does not recommend immunosuppressive 
therapy for this class, nevertheless, patients with 
Table 2. Immunosuppressants used in LN17
Immunosuppressant 
Agents Dosage






CYC = cyclosphophamide; IV = intravenous; MMF = 
mycophenolate mofetil; AZA = azathioprine; * = combined 
with MMF 1 g/day
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daily dose.19
If an adequate respond to induction therapy 
is not achieved, ACR recommend that a switch 
of the immunosuppressants from either CYC to 
MMF or from MMF to CYC accompanied by 
IV pulse steroids for 3 days.19
According to ACR, Class I and Class II LN 
does not require immunosuppressive therapy.19 
Furthermore, hydroxychloroquine (HCQ) must 
be given to all systemic lupus erythematosus 
(SLE) patients with nephritis as it has been 
proven to lower renal damage and reduce the 
risk of clotting events.19 In addition, LN patients 
with proteinuria over 0.5 g/d should be given 
renin-angiotensin system (RAS) blockers such as 
angiotensin-converting enzyme (ACE) inhibitors 
and angiotensin receptor blockers (ARBs).19 As 
for Class VI LN, it requires renal replacement 
therapy rather than immunosuppressive therapy.19
CURRENT MAINTENANCE THERAPY
The target of induction therapy in treating 
lupus nephritis (LN) is to rapidly attenuate 
inflammation process caused by accumulation 
of autoantibody immune complex and to give 
chance to parenchymal tissue for healing 
process.20 After this phase of treatment, only few 
patients achieve complete clinical remission, as 
renal response rates showed 50-80% at 1 year 
with the majority of the response was partial 
response.21 In order to consolidate remissions 
and prevent relapses of LN, one must receive 
maintenance therapy.
Guidelines of lupus nephritis treatment still 
recommends the use of either MMF or AZA as 
the choice of maintenance therapy. There was 
still no definitive first line choice between the two 
options. Based on KDIGO (2012), in making the 
decision of treatment choice, clinical adjustments 
such as pregnancy plan or occurrence of side effects 
are considered.22 The use of AZA as maintenance 
therapy is preferred if patient plan for pregnancy.23 
Treatment guidelines by ACR (2012) recommends 
the use of either mycophenolate mofetil (MMF) 
1-2 g/day or azathiprone (AZA) 2 mg/kg/day in 
maintenance therapy of LN.19
Figure 2. Induction therapy for LN according to ACR.19 
(MMF = mycophenolate mofetil; CYC = cyclosphophamide; GC = glucocorticoids; IV = intravenous; 
AZA = azathioprine; BSA = body surface area)
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There were two big clinical trials aiming 
for optimal maintenance therapy for LN, which 
were the MAINTAIN study and Aspreva Lupus 
Management Study (ALMS). These two studies 
compared effectiveness between MMF and AZA.
In ALMS trial, 227 patients were randomized 
to receive either MMF (2 g/day) or AZA (2 mg/
kg/day). The follow-up duration was 36 months. 
The primary end point was time to treatment 
failure (death, end-stage renal disease, doubling 
of serum creatinine level, renal flare, or rescue 
therapy). This trial showed that MMF was 
superior to AZA in the aspect of time to treatment 
failure (hazard ratio 0.44; 95% confidence 
interval, 0.25—0.77; P=0.003) and time to 
rescure therapy (hazard ratio <1.00; P<0.05). 
Serious adverse events occurred more in AZA 
group than in MMF group (33.3% vs 23.5%, 
P=0.11).24
In MAINTAIN trial, with the same follow 
up duration (36 months), 105 patients were 
randomized to receive either MMF or AZA with 
the same dosage.25 Time to renal flare in MMF 
and AZA group were statistically insignificant 
(19% and 25% respectively).25
The duration of therapy in maintenance 
phase is still questionable. According to KDIGO 
2012, the average duration of maintenance 
therapy was 3.5 years.22 A guideline by Spanish 
Society of Nephrology (GEAS) recommended 
that duration of maintenance therapy was 2 
years after complete remission.26 Euro-Lupus 
Nephritis trial was a ten-year follow-up study 
which showed that 53% of the patients were still 
on maintenance therapy. Advice from the Dutch’s 
guideline on LN stated that clinicians should 
taper the dose of prednisone to 10 mg every other 
day at four years after the beginning of induction 
therapy and followed by decreasing 50% dose of 
AZA or MMF 6 months later and continue until 
at least two more years.27 After 6.5 years, it is 
left to the treating clinician’s decision and the 
patient’s.28 Table 3 summarize the comparison of 
guidelines on the maintenance therapy of lupus 
nephritis class III/IV.
EVALUATION
Currently, the gold standard of care for 
patients with lupus nephritis (LN) after induction 
therapy is to administer maintenance therapy 
for around 3 years. In a subset of patients with 
clinically silent disease, the decision to stop 
maintenance therapy should be done with 
caution. In order to decide whether these patients 
Table 3. Comparison of guidelines on maintenance therapy of lupus nephritis class III/IV
Guidelines Corticosteroid Immunosuppresive Agent Choice Duration and Dosage Tapering
Kidney Disease Improving 






MMF 1-2 g/day or AZA 
1.5-2.5 mg/day
Continue at least 1 year after 
complete remission
European League Against 
Rheumatism and European 
Renal Association-European 





MMF or AZA. MMF 
was preferred if 
there was adequate 
response to MMF in 
induction phase.
Three years after complete 
remission.




MMF 1-2 g/day or AZA 
2 mg/kg/day
Not specified. The Task Force Panel 
did not vote on the rate of medication 
taper in maintenance phase.
Systemic Autoimmune Disease 
Group of the Spanish Society of 
Internal Medicine and Spanish 
Society of Nephrology (GEAS)26
Low-dose oral 
corticosteroids
MMF over AZA Two years after complete remission.
Dutch Guidelines for Diagnosis 
and Therapy of Proliferative 
Lupus Nephritis28; 2012 
Low-dose oral 
corticosteroids
MMF over AZA Taper prednisone 10 mg every other 
day at 4 years after the beginning of 
induction phase, decrease 50% dose 
of AZA or MMF after 6 months, and 
continue at least 2 more years (Total: 
6.5 years)
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do not need further therapy, repeated renal 
biopsy to confirm the histological evidence of 
non-active LN and laboratory work needs to 
be performed. Repeat kidney biopsy in patients 
who have completed and responded well to 
the maintenance course treatment can also be 
planned to decide whether the therapy should 
be discontinued.29 The reason to be cautious 
before stopping therapy is that LN could still be 
active after several years of immunosuppressive 
therapy. Renal flares after treatment withdrawal 
could lead to a more progressive chronic kidney 
injury. There are several criteria available to 
assess the renal response after therapy. However, 
those criteria are based on serum creatinine 
level, estimated glomerular filtration rate 
(eGFR), proteinuria, urine protein creatinine 
ratio (UPCR), hematuria, urinary sediment and 
cast. Furthermore, flare criteria definition has 
been based on a guideline by KDIGO which 
has criteria similar as to check renal response to 
therapy.30 Table 4 presents the relapse renal flare 
criteria based on KDIGD guidelines.
NOVEL AND EMERGING TREATMENT OF 
LUPUS NEPHRITIS
The pathogenesis of lupus nephritis (LN) is 
associated with activation of mainly B and T cells. 
Activation of B cell further leads to formation 
of plasma cells and subsequently autoimmunity 
against the kidney, which will induce kidney 
damage through inflammation process. On the 
other hand, antigen presenting cells falsely 
presents autoantigen unto T cells which induces 
further inflammatory process through activation 
of pro-inflammatory cytokines. Various pro-
inflammatory cytokines have been described 
to be implicated in the pathogenesis of LN but 
it seems that interferon-α (IFN-α) is the master 
regulator of stimulating the differentiation of B 
cells and T cells.31,32 As stated before, B cells 
play an important role in LN and therefore it 
is an attractive target in LN treatment. One 
example of popular B cell depleting agent is 
rituximab, an anti-CD20 monoclonal antibody 
which has been studied extensively with mixed 
results. Several early studies have reported 
potential benefit of rituximab. However, Lupus 
Nephritis Assessment with Rituximab Study 
(LUNAR) failed to reproduce the same results 
from previous studies.33
Currently, there is still ongoing interest in 
studying the effect of rituximab and other B 
cell depleting agents in the treatment of LN. 
Scientists have questioned the trial design of 
LUNAR study as it was rather a short-term rather 
than a long-term study. Rituximab as a B cell 
depleting agent has been argued not to resolve 
Table 4. Relapse/renal flare criteria based on KDIGO guideline22
Mild Relapse Moderate Relapse Severe Relapse
Increased of hematuria 
from <5 to >15 erythrocyte/
HPF, with >2 acanthocyte/
HPF
If baseline serum creatinine (sCr) <2 mg/dL, 
moderate relapse is defined as increased of sCr 
0.2-1 mg/dL 
If baseline creatinine <2 mg/dL, severe 
relapse is defined as increased of sCr 
>1 mg/dL.
With/without If baseline serum creatinine (sCr) >2 mg/dL, 
moderate relapse is defined as increased of sCr 
0.4-1.5 mg/dL 
If baseline creatinine >2 mg/dL, severe 
relapse is defined as increased of sCr 
>1.5 mg/dL.
Recurrence of >1 
erythrocyte, leucocyte 
(without infection), or both
With/without With/without
If baseline urine protein creatinine ratio (uPCR) 
<500 mg/g, moderate relapse is defined as 
increased of uPCR >1000 mg/g.
Increased of uPCR >5000 mg/g
If baseline uPCR 500-1000 mg/g, moderate 
relapse is defined as increased of uPCR between 
2000-5000 mg/g.
If baseline uPCR >1000 mg/g, moderate relapse 
is defined as increased of uPCR >2 times with 
absolute uPCR <5000 mg/g.
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acute inflammation of the kidney, but rather it 
might prevent future renal flares since it works 
by inhibiting autoimmunity response and not 
the acute inflammation process.37 To address 
this concern, a trial is underway to investigate 
the effect of similar B cell depleting agent like 
rituximab, which involves obinutuzumab, a type-
2 chimeric, anti-CD20 monoclonal antibody. 
Early initial studies reported better results than 
rituximab. Therefore, it is currently in clinical 
trial to evaluate the depletion of B cells in kidney 
tissues.38.39
 Another example of potential B cell 
depleting agents are belimumab and tabalumab, 
an anti-BAFF monoclonal antibody. B cells 
activating factors (BAFF) is needed to induce 
B cell proliferation and survival, thus the use of 
this agent in LN treatment is promising.40 Current 
topic suggests that BAFF level increases after 
B cell depletion. It is stated that reactivation of 
B cells in BAFF-rich environment after B cells 
depletion will lead to more autoreactive B cells, 
which bypass the tolerance checkpoints. It is 
known that high BAFF level is associated with 
renal flares in SLE. Hence, it is suggested that 
targeting BAFF after initial B cell depletion is 
essential to prevent reactivation of B cells and 
hopefully make these B cells more tolerant, 
less autoreactive, and more sustained clinical 
response. The immune tolerance network 
CALIBRATE study is currently testing this 
hypothesis in clinical trial.41
Plasma cells are also an interesting target in 
SLE. It is a product of B cell activation which 
produces autoimmunity against self-antigen. 
Even though B cell depleting agents have 
been widely used, those agents do not directly 
eliminate all plasma cells which have been 
formed before the therapy is given.42 Plasma 
cells, especially the long-lived one, can produce 
autoantibody and have been found in SLE during 
flare. Current standard treatment does not target 
the plasma cells in order to supress the long-lived 
plasma cells, but rather it emphasizes more on 
B cells depletion.43 Proteasome inhibitor targets 
the plasma cells and induces apoptosis. Several 
example of its agents are bortezomib, carfilzomib, 
delanzomib, and ixazomib. Proteasome inhibitor 
is also known to have dual mechanism of action 
as anti-inflammatory by suppresing IFN-α and as 
anti-autoimmunity. Currently, there are several 
clinical trials evaluating patients who are not 
responsive to initial standard of care treatment.44
IFN-α is a key biological target to attenuate 
inflammatory process in SLE and LN patients. An 
example of an IFN-α which is currently in clinical 
trial is Anifrolumab, a monoclonal antibody that 
targets IFN-α receptor 1. Anifrolumab has shown 
its efficacy in non-renal SLE when compared to 
placebo in patients who have high type IFN-α 
signature. The TULIP LN 1 study is undergoing 
an investigation of anifrolumab combined with 
the gold standard treatment for proliferative LN. 
In this study, the researchers divides patients into 
Table 5. Response criteria definitions
Study Complete Remission Partial Remission
National Institute of Health (NIH)34 SCr <130% from the lowest value, 
proteinuria <1 gr/24 hour, hematuria 
<10 red blood cells/HPF, without 
evidence of cellular cast
SCr <150% from the lowest value
Euro-lupus Nephritis Trial (ELNT)35 This guideline does not divide remission criteria into complete or partial. 
Remission criterias are as follow:
Hematuria <10 red blood cell/HPF, proteinuria <1 gr/24 hour, sCr value does not 
increase 2 times above normal value.
American College of Rheumatology 
(ACR)19
50% decrease of uPCR + uPCR <0.2 50% decrease of uPCR + uPCR 0.2-
2.0
KDIGO36 SCr returns to baseline, plus decrease 
of uPCR <500 mg/gr (<50 mg/mmol).
Stabilized (±25%) or improvement 
of SCr but not return to normal, plus 
decrease of uPCR >50%. If nephrotic 
proteinuria is found, uPCR should 
decrease >50%.
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two groups. The first group consists of patients 
who have high IFN-α and the other group who 
have low IFN-α concentration. This is necessary 
to prevent treating patients who do not actually 
express the drug’s target which predictably will 
result in treatment failure.45
Another appealing therapy strategy in 
LN is to target complement pathway. This 
alternative pathway seems to be important to 
cause kidney damage through inflammation 
process.46 Current example of complement 
activation products include C3bi, C5a, and 
C5b-9. There is a hypothesis stating that 
inclusion of complement targeted therapy in 
combination with  gold standard treatment 
might help to attenuate inflammation and reduce 
the use of corticosteroid.47 However, evidence 
of its efficacy in LN has not been extensively 
evaluated. Therefore, further research regarding 
agents which target this pathway is important.48 
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